DK2653873T3 - Sammensætninger og anvendelser til behandling af multipel sklerose - Google Patents

Sammensætninger og anvendelser til behandling af multipel sklerose Download PDF

Info

Publication number
DK2653873T3
DK2653873T3 DK13169139.6T DK13169139T DK2653873T3 DK 2653873 T3 DK2653873 T3 DK 2653873T3 DK 13169139 T DK13169139 T DK 13169139T DK 2653873 T3 DK2653873 T3 DK 2653873T3
Authority
DK
Denmark
Prior art keywords
compositions
treatment
multiple sclerosis
sclerosis
Prior art date
Application number
DK13169139.6T
Other languages
English (en)
Other versions
DK2653873T1 (da
Inventor
Matvey E Lukashev
Gilmore O'neill
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39682314&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2653873(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of DK2653873T1 publication Critical patent/DK2653873T1/da
Application granted granted Critical
Publication of DK2653873T3 publication Critical patent/DK2653873T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90209—Oxidoreductases (1.) acting on NADH or NADPH (1.6), e.g. those with a heme protein as acceptor (1.6.2) (general), Cytochrome-b5 reductase (1.6.2.2) or NADPH-cytochrome P450 reductase (1.6.2.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
DK13169139.6T 2007-02-08 2008-02-07 Sammensætninger og anvendelser til behandling af multipel sklerose DK2653873T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88892107P 2007-02-08 2007-02-08
EP08725256.5A EP2137537B8 (en) 2007-02-08 2008-02-07 Compositions and Uses for Treating Multiple Sclerosis

Publications (2)

Publication Number Publication Date
DK2653873T1 DK2653873T1 (da) 2022-05-30
DK2653873T3 true DK2653873T3 (da) 2022-07-25

Family

ID=39682314

Family Applications (3)

Application Number Title Priority Date Filing Date
DK13169139.6T DK2653873T3 (da) 2007-02-08 2008-02-07 Sammensætninger og anvendelser til behandling af multipel sklerose
DK13156663.0T DK2629097T1 (da) 2007-02-08 2008-02-07 NRF2-screeningsassays og relaterede fremgangsmåder og sammensætninger
DK08725256.5T DK2137537T3 (da) 2007-02-08 2008-02-07 Sammensætninger og anvendelser til behandling af multipel sklerose

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK13156663.0T DK2629097T1 (da) 2007-02-08 2008-02-07 NRF2-screeningsassays og relaterede fremgangsmåder og sammensætninger
DK08725256.5T DK2137537T3 (da) 2007-02-08 2008-02-07 Sammensætninger og anvendelser til behandling af multipel sklerose

Country Status (18)

Country Link
US (8) US20110112196A1 (da)
EP (10) EP2680007A1 (da)
CY (5) CY1114340T1 (da)
DE (2) DE13169139T1 (da)
DK (3) DK2653873T3 (da)
ES (3) ES2424022T3 (da)
FI (2) FI2629097T1 (da)
FR (2) FR14C0050I1 (da)
HR (2) HRP20130707T1 (da)
HU (1) HUS2300001I1 (da)
LT (2) LT2653873T (da)
LU (1) LU92487I2 (da)
NO (2) NO2014015I1 (da)
PL (2) PL2137537T3 (da)
PT (2) PT2137537E (da)
RS (2) RS63489B1 (da)
SI (2) SI2137537T1 (da)
WO (1) WO2008097596A2 (da)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
WO2005023241A1 (en) 2003-09-09 2005-03-17 Fumapharm Ag The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
SI2801354T1 (sl) * 2004-10-08 2017-07-31 Forward Pharma A/S Farmacevtske sestave z nadzorovanim sproščanjem, ki zajemajo ester fumarne kisline
DK2653873T3 (da) 2007-02-08 2022-07-25 Biogen Ma Inc Sammensætninger og anvendelser til behandling af multipel sklerose
PT2139467T (pt) * 2007-02-08 2016-12-16 Biogen Ma Inc Neuroproteção em doenças desmielinizantes
HUE043175T2 (hu) 2008-01-11 2019-08-28 Reata Pharmaceuticals Inc Szintetikus triterpenoidok és alkalmazásuk betegség kezelésében
MX339476B (es) 2008-04-18 2016-05-27 Reata Pharmaceuticals Inc Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
ES2703274T3 (es) 2008-04-18 2019-03-07 Reata Pharmaceuticals Inc Moduladores de la inflamación antioxidantes: derivados del ácido oleanólico con modificaciones amino y otras en C-17
CN104250280A (zh) 2008-04-18 2014-12-31 里亚塔医药公司 抗氧化剂炎症调节剂:c-17同系化齐墩果酸衍生物
KR101713140B1 (ko) 2008-04-18 2017-03-08 리타 파마슈티컬스 잉크. Ｃ-환에서 포화된 산화방지성 염증 조절제 올레아놀산 유도체
US9085527B2 (en) 2008-07-08 2015-07-21 Catabasis Pharmaceuticals, Inc. Fatty acid acylated salicylates and their uses
EP2309860B1 (en) 2008-07-22 2014-01-08 Trustees of Dartmouth College Monocyclic cyanoenones and methods of use thereof
DK2334378T3 (da) 2008-08-19 2014-07-07 Xenoport Inc Prodrugs af methylhydrogenfumarat, farmaceutiske sammensætninger deraf og fremgangsmåder til anvendelse
KR101699912B1 (ko) 2009-01-09 2017-01-25 포워드 파마 에이/에스 1종 이상의 푸마르산 에스테르를 침식 매트릭스에 함유하는 제제
EP3466420A1 (en) * 2009-04-29 2019-04-10 Biogen MA Inc. Dimethyl fumarate for the treatment of friedreich ataxia
DK2521447T3 (da) 2010-01-08 2017-09-18 Catabasis Pharmaceuticals Inc Fedtsyrefumarater og deres anvendelser
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
ES2679918T3 (es) 2010-02-18 2018-08-31 Vtv Therapeutics Llc Derivados de imidazol condensados sustituidos, composiciones farmacéuticas y métodos de uso de los mismos
CA2820586A1 (en) * 2010-12-07 2012-06-14 Teva Pharmaceutical Industries Ltd. Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
HRP20171859T1 (hr) 2010-12-17 2018-01-26 Reata Pharmaceuticals, Inc. Pirazolil i pirimidinil triciklički enoni kao antioksidacijski modulatori upale
CA2829618C (en) 2011-03-11 2019-07-09 Reata Pharmaceuticals, Inc. C4-monomethyl triterpenoid derivatives and methods of use thereof
WO2012145420A1 (en) * 2011-04-18 2012-10-26 Rutgers, The State University Of New Jersey Composition, synthetic process and use of new antioxidant inflammation modulators
US20140142095A1 (en) * 2011-04-28 2014-05-22 Serket Pharma, Llc Agents useful for treating friedreich's ataxia and other neurodegenerative diseases
EP2713724A4 (en) * 2011-05-26 2015-03-11 Biogen Idec Inc METHODS OF TREATING MULTIPLE SCLEROSIS AND PRESERVING AND / OR INCREASING MYELINE CONTENT
JP6385273B6 (ja) 2011-06-08 2023-12-15 バイオジェン・エムエイ・インコーポレイテッド 高純度結晶性ジメチルフマラートの調製方法
US20140256767A1 (en) 2011-10-31 2014-09-11 The Broad Institute, Inc. Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators
HK1202885A1 (en) 2011-12-16 2015-10-09 Biogen Ma Inc. Silicon-containing fumaric acid esters
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US20130259856A1 (en) * 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
JP6283346B2 (ja) * 2012-03-30 2018-02-21 ネステク ソシエテ アノニム ４−オキソ−２−ペンテン酸及び脳の健康
DK3444261T3 (da) 2012-04-27 2021-03-08 Reata Pharmaceuticals Inc 2,2-difluorpropionamidderivat af bardoxolonmethyl, farmaceutiske sammensætninger og polymorfer deraf til anvendelse ved behandling af visse lidelser
US9556222B2 (en) 2012-06-15 2017-01-31 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
JP2015527372A (ja) 2012-08-22 2015-09-17 ゼノポート，インコーポレイティド 副作用を低減させるモノメチルフマレートおよびそのプロドラッグの投与方法
US20140348915A9 (en) 2012-08-22 2014-11-27 Xenoport, Inc. Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof
PL2892912T3 (pl) 2012-09-10 2019-10-31 Reata Pharmaceuticals Inc C17-alkanodiylowe i alkenodiylowe pochodne kwasu oleanolowego i sposoby ich zastosowania
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
WO2014058982A2 (en) * 2012-10-10 2014-04-17 Temple University Of The Commonwealth System Of Higher Education Nuclear factor-erythroid 2 related factor 2 (nrf2) biosensors and modulators of nrf2
US20140171504A1 (en) 2012-12-14 2014-06-19 Georgia Regents Research Institute, Inc. Methods of Treating Sickle Cell Disease and Related Disorders Using Fumaric Acid Esters
JP6506174B2 (ja) 2012-12-21 2019-04-24 バイオジェン エムエー インコーポレイテッド 重水素置換されたフマル酸誘導体
US10905663B2 (en) 2013-03-05 2021-02-02 The University Of Chicago Treatment of demyelinating disorders
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
CN105452213B (zh) 2013-03-14 2017-09-22 阿尔克梅斯制药爱尔兰有限公司 富马酸酯前体药物及其在治疗多种疾病中的应用
WO2014160633A1 (en) * 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
US9302977B2 (en) 2013-06-07 2016-04-05 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
ES2526979B1 (es) * 2013-07-17 2015-10-28 Fundación Para La Investigación Biomédica Del Hospital Universitario De La Princesa Uso del 3-(2-isotiocianatoetil)-5-metoxi-1H-indol para el tratamiento de enfermedades neurodegenerativas
TW201516020A (zh) 2013-09-06 2015-05-01 Xenoport Inc （ｎ，ｎ－二乙基胺甲醯基）甲基（２ｅ）丁－２－烯－１，４－二酸甲酯之晶形、合成方法及用途
JP6317440B2 (ja) 2013-10-29 2018-04-25 プレジデント アンド フェローズ オブ ハーバード カレッジ 酸化ストレスを阻害するための方法および組成物
CN103768045B (zh) * 2013-10-30 2015-10-07 苏州大学附属第一医院 富马酸二甲酯在制备治疗蛛网膜下腔出血后早期脑损伤药物的应用
GB201401465D0 (en) 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
CA2940845C (en) 2014-02-24 2019-09-24 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
EP3110408B1 (en) 2014-02-28 2019-01-16 Banner Life Sciences LLC Controlled release enteric soft capsules of fumarate esters
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
EP2924127A1 (en) * 2014-03-27 2015-09-30 Université Paul Sabatier Toulouse III Method and kit for prognosis of OPA1 gene induced diseases, e.g. Kjers optic atrophy.
KR20170005434A (ko) 2014-04-29 2017-01-13 테바 파마슈티컬 인더스트리즈 리미티드 높은 장애 상태를 갖는 재발-완화형 다발성 경화증(rrms) 환자 치료용 라퀴니모드
DE102014010832A1 (de) 2014-07-24 2016-01-28 Peter Krause Verwendung von medikamentösen Ingredienzien zur Behandlung von Multiple Sklerose
WO2016089648A1 (en) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
MA41139B1 (fr) 2014-12-11 2026-02-27 Laboratoires Juvise Pharmaceuticals Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque
DK3256125T3 (da) 2014-12-11 2022-03-21 Actelion Pharmaceuticals Ltd Doseringsregimen for ponesimod, en selektiv s1p1-receptoragonist
MA41785A (fr) 2015-03-20 2018-01-23 Biogen Ma Inc Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques
EP3273951B1 (en) 2015-03-27 2020-07-29 Symbionyx Pharmaceuticals Inc. Compositions and methods for treating psoriasis
US10085961B2 (en) 2015-06-01 2018-10-02 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of dimethyl fumarate
CN105087644A (zh) * 2015-07-23 2015-11-25 山东大学 一种高通量筛选具有Nrf2激活活性的化合物的方法
US10213411B2 (en) 2015-08-27 2019-02-26 Vijaykumar Rajasekhar Use of prodrugs of fumarates in treating heart failure diseases
EA201890767A1 (ru) 2015-09-23 2019-09-30 Рита Фармасьютикалз, Инк. C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
US10463642B2 (en) 2016-02-01 2019-11-05 Vijaykumar Rajasekhar Methods of treating heart failure diseases using prodrugs of methyl hydrogen fumarate
CA3040914A1 (en) 2016-11-03 2018-05-24 Juno Therapeutics, Inc. Combination therapy of a cell based therapy and a microglia inhibitor
AU2018275891B2 (en) 2017-06-02 2025-02-27 Juno Therapeutics, Inc. Articles of manufacture and methods related to toxicity associated with cell therapy
CN111225675B (zh) 2017-06-02 2024-05-03 朱诺治疗学股份有限公司 使用过继细胞疗法治疗的制品和方法
US20210071258A1 (en) 2017-09-01 2021-03-11 Juno Therapeutics, Inc. Gene expression and assessment of risk of developing toxicity following cell therapy
US11434502B2 (en) 2017-10-16 2022-09-06 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (ALS)
EP4454654A3 (en) 2017-10-16 2025-02-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
WO2019089848A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
EP3810141A1 (en) 2018-06-20 2021-04-28 Reata Pharmaceuticals, Inc. Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith
CA3103963A1 (en) 2018-07-02 2020-01-09 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
WO2020010035A1 (en) 2018-07-02 2020-01-09 Voyager Therapeutics, Inc. Cannula system
US11013723B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms of a thiazolidinone compound, compositions and methods of use thereof
US11014940B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Thiazolidinone and oxazolidinone compounds and formulations
US11186556B1 (en) 2018-10-16 2021-11-30 Celgene Corporation Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
US11014897B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof
SG11202105380RA (en) 2018-11-30 2021-06-29 Juno Therapeutics Inc Methods for dosing and treatment of b cell malignancies in adoptive cell therapy
BR112021010354A2 (pt) 2018-11-30 2021-11-03 Juno Therapeutics Inc Métodos para o tratamento usando terapia celular adotiva
KR102891865B1 (ko) 2019-07-19 2025-11-26 리아타 파마슈티컬즈, 아이엔씨. C17 극성-치환된 헤테로방향족 합성 트리터페노이드 및 그의 사용 방법
WO2021113770A1 (en) 2019-12-06 2021-06-10 Juno Therapeutics, Inc. Methods related to toxicity and response associated with cell therapy for treating b cell malignancies
WO2021142062A1 (en) 2020-01-10 2021-07-15 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
EP4117785A4 (en) * 2020-03-13 2024-04-17 Marc J. Simard METHODS OF TREATING MULTIPLE SCLEROSIS
MX2023014395A (es) 2021-06-04 2023-12-15 Zim Laboratories Ltd Composiciones de liberacion retardada de dimetilfumarato.

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2530372A1 (de) 1975-07-08 1977-01-13 Walter Dr Schweckendiek Pharmazeutische zubereitungen zur behandlung von psoriasis
DE2621214C3 (de) 1976-05-13 1981-11-12 Koronis Gmbh Chemisch-Pharmazeutische Praeparate, 5441 Sassen Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und desen Mineralsalzen
JPS5824104B2 (ja) 1977-12-06 1983-05-19 博衛 小川 フマル酸製剤
DE2840498C2 (de) 1978-09-18 1980-04-10 Walter Dr. 6700 Ludwigshafen Schweckendiek Pharmazeutische Zubereitungen zur Behandlung von Psoriasis
DE3127432A1 (de) 1981-07-11 1983-02-03 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von fumarsaeuremonoester
CH664150A5 (de) 1985-01-15 1988-02-15 Peter Paul Prof Dr Speiser Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen.
US5149695A (en) 1985-01-15 1992-09-22 Speiser Peter P Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same
JPS61194020A (ja) 1985-02-22 1986-08-28 Dai Ichi Seiyaku Co Ltd 網膜症治療剤
US4855305A (en) 1987-03-23 1989-08-08 Applied Medical Research Compositions and methods of effecting contraception utilizing melatonin
IL83775A (en) 1987-09-04 1991-12-15 Dexter Chemical Corp Amino acid esters and amides of fumaric acid and pharmaceutical compositions containing them for use in the treatment of psoriasis
US5214196A (en) 1987-09-04 1993-05-25 Dexter Chemical Corporation Diethyl ester of di-glycyl fumaramide
US5242905A (en) 1987-09-04 1993-09-07 Dexter Chemical Corporation Pharmaceutical compositions for the treatment of psoriasis
US5424332A (en) 1987-10-19 1995-06-13 Speiser; Peter P. Pharmaceutical composition and process for the production thereof
US4959389A (en) 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
DE3834794A1 (de) 1988-10-12 1990-04-19 F Schielein Oral zu verabreichendes mittel zur behandlung von psoriasis
WO1992012952A1 (en) 1991-01-18 1992-08-06 Dexter Chemical Corporation Malic acid derivatives and compositions for the treatment of psoriasis
IT1251166B (it) 1991-08-09 1995-05-04 Chiesi Farma Spa Derivati di geneserina,loro preparazione e composizioni farmaceutiche che li contengono
US5459667A (en) 1993-01-22 1995-10-17 Sumitomo Electric Industries, Ltd. Navigation apparatus for informing vehicle driver of information regarding travel route
AU7060394A (en) 1993-06-08 1995-01-03 Raymond K. Brown Therapeutic compositions and methods of use
JPH06345644A (ja) 1993-06-10 1994-12-20 Unitika Ltd 自己免疫性疾患治療剤
US5407772A (en) 1993-11-30 1995-04-18 Xerox Corporation Unsaturated polyesters
DK0750616T3 (da) 1994-03-16 2001-07-23 Cenes Ltd Syreadditionssalte af 2,3,4,5-tetrahydro-1H-3-benzazapinforbindelser
WO1997011092A1 (en) 1994-04-07 1997-03-27 Nippon Shinyaku Co., Ltd. Cyclosporin phosphate derivatives and medicinal composition
US6217847B1 (en) 1994-07-01 2001-04-17 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US6576236B1 (en) 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
US5650135A (en) 1994-07-01 1997-07-22 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
GB2291422A (en) 1994-07-18 1996-01-24 Fujisawa Pharmaceutical Co 4-phenyl-pyrido[2,3-b]pyrazin-4-ones
US5763190A (en) 1994-09-21 1998-06-09 The Trustees Of The University Of Pennsylvania Methods for the identification of compounds capable of inducing the nuclear translocation of a receptor complex comprising the glucocoticoid receptor type II and viral protein R interacting protein
CN1125141A (zh) 1994-12-22 1996-06-26 杭州中美华东制药有限公司 一种含环孢菌素a的固体分散物及其外用剂型上的用途
JP2535141B2 (ja) 1995-01-17 1996-09-18 中外製薬株式会社 フマル酸含有徐放性製剤
EP0850061A1 (en) 1995-09-13 1998-07-01 Takeda Chemical Industries, Ltd. Immunosuppressant
HU9502843D0 (en) 1995-09-29 1995-11-28 Livigene Ltd Pharmaceutical composition
JP4004567B2 (ja) 1996-02-14 2007-11-07 アステラス製薬株式会社 Ｗｂ２６６３ｂ物質を含有する免疫抑制剤
KR970064620A (ko) 1996-03-05 1997-10-13 임성기 사이클로스포린-함유 외용약제 조성물
WO1997044054A2 (en) 1996-05-22 1997-11-27 University Of Alberta Type-2 chemokine binding proteins and methods of use therefor
AU7003096A (en) 1996-06-21 1998-01-07 Jury Evgenievich Belyaev Semi-finished product for producing drug bases, bases obtained using the same and variants, and drugs obtained using these bases and variants
EP1886677A1 (en) 1996-07-26 2008-02-13 Susan P. Perrine Use of an inducing agent for the treatment of blood, viral and cellular disorders
WO1998027970A2 (en) 1996-12-24 1998-07-02 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
US5972363A (en) 1997-04-11 1999-10-26 Rohm And Haas Company Use of an encapsulated bioactive composition
DE19721099C2 (de) 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
AU760140B2 (en) 1997-10-24 2003-05-08 John P. Blass Nutritional supplement for cerebral metabolic insufficiencies
US20050245612A1 (en) 2004-05-03 2005-11-03 Blass John P Pharmaceutical compositions for metabolic insufficiencies
DE19814358C2 (de) 1998-03-31 2002-01-17 Fumapharm Ag Muri Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn
DE19839566C2 (de) 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
DE19848260C2 (de) 1998-10-20 2002-01-17 Fumapharm Ag Muri Fumarsäure-Mikrotabletten
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
DE10000577A1 (de) 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
WO2001059072A1 (en) 2000-02-11 2001-08-16 Philadelphia Health And Education Corporation Differentiation of bone marrow cells into neuronal cells and uses therefor
US6812248B2 (en) 2000-07-05 2004-11-02 John Hopkins University School Of Medicine Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymes
US20020173549A1 (en) 2000-11-08 2002-11-21 Wurtman Richard J. Compositions and methods for treatment of mild cognitive impairment
US6451667B1 (en) 2000-12-21 2002-09-17 Infineon Technologies Ag Self-aligned double-sided vertical MIMcap
AU2002219236B2 (en) 2001-01-12 2006-02-09 Biogen International Gmbh Fumaric acid amides
DE10101307A1 (de) 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
US7056950B2 (en) 2001-02-14 2006-06-06 Matthias Rath Compositions of biochemical compounds involved in bioenergy metabolism of cells
RU2189813C1 (ru) 2001-06-01 2002-09-27 Российский научно-исследовательский институт гематологии и трансфузиологии Лекарственное средство антигипоксического действия
US20030104997A1 (en) 2001-09-05 2003-06-05 Black Ira B. Multi-lineage directed induction of bone marrow stromal cell differentiation
EP1435930A2 (en) 2001-10-15 2004-07-14 National Research Council Of Canada Anti-glycation agents for preventing age-, diabetes-, and smoking-related complications
DE10217314A1 (de) 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
WO2005023241A1 (en) 2003-09-09 2005-03-17 Fumapharm Ag The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
DE10342423A1 (de) 2003-09-13 2005-04-14 Heidland, August, Prof. Dr.med. Dr.h.c. Verwendung von Fumarsäurederivaten zur Prophylaxe und zur Behandlung von Genomschäden
SI2801354T1 (sl) 2004-10-08 2017-07-31 Forward Pharma A/S Farmacevtske sestave z nadzorovanim sproščanjem, ki zajemajo ester fumarne kisline
WO2006050730A1 (en) 2004-11-10 2006-05-18 Aditech Pharma Ab Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
JP2008520717A (ja) 2004-11-19 2008-06-19 バイオジェン・アイデック・エムエイ・インコーポレイテッド 多発性硬化症についての処置
US7638119B2 (en) 2004-12-02 2009-12-29 Wisconsin Alumni Research Foundation Method of diminishing the symptoms of neurodegenerative disease
EP1674082A1 (de) 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
MX2007010068A (es) 2005-02-16 2007-10-10 Schering Corp Piperazino-piperidinas con actividad antagonista de cxcr3.
MX2007009946A (es) 2005-02-16 2007-09-26 Schering Corp Piperazin-piperidinas sustituidas con piridilo y fenilo con actividad antagonista de cxcr3.
CA2598460C (en) 2005-02-16 2013-05-07 Schering Corporation Amine-linked pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
EP1856098B1 (en) 2005-02-16 2012-08-01 Schering Corporation Pyrazinyl substituted piperazine-piperidines with cxcr3 antagonist activity
CN101146793A (zh) 2005-02-16 2008-03-19 先灵公司 具有cxcr3拮抗剂活性的新的杂环取代了的吡啶或苯基化合物
CN101163692B (zh) 2005-02-16 2012-01-18 先灵公司 具有cxcr3拮抗活性的杂环取代的哌嗪
US7879838B2 (en) 2005-02-16 2011-02-01 Schering Corporation Heteroaryl substituted pyrazinyl-piperazine-piperidines with CXCR3 antagonist activity
DE102005022845A1 (de) 2005-05-18 2006-11-23 Fumapharm Ag Thiobernsteinsäurederivate und deren Verwendung
WO2007005879A2 (en) 2005-07-01 2007-01-11 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
WO2007006307A2 (en) 2005-07-07 2007-01-18 Aditech Pharma Ab Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
US20100144651A1 (en) 2005-07-07 2010-06-10 Aditech Pharma Ab Novel glucopyranose esters and glucofuranose esters of alkyl- fumarates and their pharmaceutical use
WO2007042035A2 (en) 2005-10-07 2007-04-19 Aditech Pharma Ab Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
US20080299196A1 (en) 2005-10-07 2008-12-04 Aditech Pharma Ab Controlled Release Pharmaceutical Compositions Comprising a Fumaric Acid Ester
US20080089861A1 (en) 2006-07-10 2008-04-17 Went Gregory T Combination therapy for treatment of demyelinating conditions
DK2653873T3 (da) 2007-02-08 2022-07-25 Biogen Ma Inc Sammensætninger og anvendelser til behandling af multipel sklerose
PT2139467T (pt) 2007-02-08 2016-12-16 Biogen Ma Inc Neuroproteção em doenças desmielinizantes
EP3466420A1 (en) 2009-04-29 2019-04-10 Biogen MA Inc. Dimethyl fumarate for the treatment of friedreich ataxia
PT2533634E (pt) 2010-02-12 2015-12-28 Biogen Ma Inc Neuroproteção em doenças desmielinizantes
JP2013221921A (ja) 2012-04-19 2013-10-28 Heidenhain Kk ロータリーエンコーダ

Also Published As

Publication number Publication date
DK2137537T3 (da) 2013-07-29
FI2629097T1 (fi) 2022-06-15
EP2629097A1 (en) 2013-08-21
ES2916649T3 (es) 2022-09-21
DE13156663T1 (de) 2022-07-14
LTPA2023503I1 (da) 2023-02-10
PL2653873T1 (pl) 2022-07-04
SI2137537T1 (sl) 2013-10-30
NO2014015I1 (no) 2014-06-26
HRP20130707T1 (en) 2013-09-30
PL2653873T3 (pl) 2022-08-22
CY2023004I1 (el) 2023-06-09
PT2137537E (pt) 2013-08-22
ES2916649T1 (es) 2022-07-04
EP2653873B8 (en) 2022-08-24
EP2653873B1 (en) 2022-07-20
EP2137537A2 (en) 2009-12-30
US20150366803A1 (en) 2015-12-24
US20130303613A1 (en) 2013-11-14
HK1139204A1 (en) 2010-09-10
EP2680008A1 (en) 2014-01-01
SI2653873T1 (sl) 2022-09-30
EP2518511A1 (en) 2012-10-31
EP2680010A1 (en) 2014-01-01
LU92487I2 (fr) 2015-11-02
FR14C0050I1 (fr) 2014-08-08
CY1114340T1 (el) 2016-08-31
EP2653873A1 (en) 2013-10-23
FR23C1003I1 (fr) 2023-03-10
CY2023002I1 (el) 2023-06-09
LT2653873T (lt) 2022-10-10
WO2008097596A3 (en) 2008-12-11
ES2424022T3 (es) 2013-09-26
PL2137537T3 (pl) 2013-10-31
WO2008097596A2 (en) 2008-08-14
FIC20230002I1 (fi) 2023-01-16
CY1125379T1 (el) 2025-05-09
US20110112196A1 (en) 2011-05-12
EP2137537B1 (en) 2013-05-29
EP2680009A1 (en) 2014-01-01
DK2653873T1 (da) 2022-05-30
EP2680007A1 (en) 2014-01-01
DE13169139T1 (de) 2022-07-14
EP2680006A1 (en) 2014-01-01
HUS2300001I1 (hu) 2023-02-28
PT2653873T (pt) 2022-07-26
US20120259012A1 (en) 2012-10-11
US20120196931A1 (en) 2012-08-02
US20130317103A1 (en) 2013-11-28
RS52922B (sr) 2014-02-28
DK2629097T1 (da) 2022-05-30
EP2137537B8 (en) 2016-06-01
NO2023001I1 (no) 2023-01-02
US20180263906A1 (en) 2018-09-20
CY2023004I2 (el) 2023-06-09
ES2916604T1 (es) 2022-07-04
US20200016072A1 (en) 2020-01-16
CY2014026I2 (el) 2016-10-05
FR23C1003I2 (fr) 2024-01-12
CY2014026I1 (el) 2016-10-05
US8399514B2 (en) 2013-03-19
RS63489B1 (sr) 2022-09-30
EP4137819A1 (en) 2023-02-22
HRP20220902T3 (hr) 2022-10-14

Similar Documents

Publication Publication Date Title
DK2137537T3 (da) Sammensætninger og anvendelser til behandling af multipel sklerose
DK2570467T3 (da) Sammensætninger af tetrafluorpropen og carbonhydrider
DK2478907T3 (da) Sammensætninger til behandling af kræft
DK3354276T3 (da) Sammensætninger til behandlingen af gastrointestinal inflammation
DK2220116T3 (da) Sammensætninger og fremgangsmåder til terapien og diagnosticeringen af influenza
DK2131856T3 (da) Sammensætninger og fremgangsmåder til forebyggelsen og behandlingen af autoimmune tilstande
DK2155188T3 (da) Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft
DK2181330T3 (da) Sammensætninger og midler til diagnosticering af mikrobielle infektioner
DK2124999T3 (da) Activin-actrii antagonister og anvendelser til behandling af anæmi
DK2474321T3 (da) Sammensætninger til behandling af collagenmedierede sygdomme
DK2796469T3 (da) Hidtil ukendte sammensætninger og fremgangsmåder til behandling af IgE-medierede forstyrrelser
DK2513023T3 (da) Sammensætninger og anvendelser af cis-1,1,1,4,4,4-hexafluor-2-buten
DK1874781T3 (da) Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme
DK2470656T3 (da) Sammensætning til hæmning af genekspression og anvendelser heraf
DK2894165T5 (da) Fremgangsmåder og sammensætninger til behandling af komplementforbundne forstyrrelser
DK3263589T5 (da) Peptidsekvenser og sammensætninger
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
DK2445912T3 (da) Ny forbindelse anvendelig til behandlingen af degenerative og inflammatoriske sygdomme
DK2066339T3 (da) Sammensætninger og fremgangsmåder til forstærkning af immunreaktioner
PL2205720T3 (pl) Kompozycja do leczenia stwardnienia rozsianego
DK2254569T3 (da) Ginsenosid-sammensætninger af protopanaxadiol-typen og anvendelser deraf
BRPI0911612A2 (pt) composições e métodos para o tratamento da esclerose múltipla.
DK2069467T3 (da) Adskillende sammensætninger og fremgangsmåder til anvendelse
DK2117525T3 (da) Anvendelse af 1-phenyl-3-dimethylamino-propanforbindelser til behandling af neuropatismerte
DK2216021T3 (da) Farmaceutisk sammensætning til behandling af overaktiv blære